SANTA CLARA, CA - Aug 9, 2005 - MDM Group, Inc. (OTC.PK: MDDM) advises that its Biodefense Division has entered into agreement with AvaxisBio for the development of a smallpox vaccine designed for safe and effective public immunization to counter bioterrorism. AvaxisBio is developing a vaccine by rational design, made from small peptide molecules based on selected portions of the Variola virus genome selected for optimal effects on the human immune system.
